BerGenBio

BERGENBIO ASA: DISCLOSURE OF LARGE SHAREHOLDINGS-PROXIES RECEIVED IN CONNECTION WITH THE AGM 19TH MARCH 2021

Bergen, Norway - 15 March 2021: BerGenBio ASA (OSE:BGBIO) will be holding its

Annual General Meeting (virtually) on 19 March 2021 at 15:00 hours (CET).

The chairman of the board of directors of BerGenBio ASA ("BergenBio"), Sveinung

Hole, has received proxies to vote at BerGenBio's Annual General Meeting to be

held on 19 March 2021 for a total of 7,570,836 shares, representing approx.

8.62% of the total share capital in BerGenBio ASA.

The proxies received are valid only for the Annual General Meeting to be held on

19 March 2021 and will automatically lapse thereafter.

- END -

About?BerGenBio?ASA

BerGenBio?is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate,?bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer, leukaemia

and COVID-19. A first-in-class functional blocking anti-AXL

antibody,?tilvestamab, is undergoing?phase I clinical testing. In

parallel,?BerGenBio?is developing?a?companion diagnostic test to identify

patient populations most likely to benefit from ?AXL inhibition: this is

expected to facilitate more efficient registration trials supporting a precision

medicine-based commercialisation strategy.

BerGenBio?is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Contacts

Richard Godfrey, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

+47 917 86?513

This information is subject to disclosure pursuant to section 4-2 of the

Norwegian Securities Trading Act.

AI Terminal